Sign In
Buy VANI
$1.28
-0.0200 (-1.54%)
At Close: Jun 03, 2026
Vivani Medical Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
07:30am, Monday, 31'st Mar 2025
Successful initial administration and full enrollment in first-in-human LIBERATE-1 ™ study of NPM-115 (exenatide implant) in obese and overweight subjects with top-line data expected in mid-2025
Vivani Medical Announces $8.25M Private Placement Equity Financing
07:32am, Thursday, 27'th Mar 2025
Financing strengthens balance sheet, extending expected runway into the second quarter of 2026 Enables accelerated development of NPM-139, Company's once or twice-yearly GLP-1 (semaglutide) implant un
Vivani Medical Announces Positive Preclinical Weight Loss Data for NPM-139 Semaglutide Implant, with Potential for Once-Yearly Dosing
07:30am, Wednesday, 26'th Mar 2025
NanoPortal™ technology successfully delivers semaglutide, the active ingredient in Ozempic®/Wegovy®, in a preclinical study with NPM-139 (semaglutide implant)
Vivani Medical to Present at the Emerging Growth Conference on March 27, 2025
08:30am, Monday, 24'th Mar 2025
ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (NASDAQ: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug impla
What Makes Vivani Medical (VANI) a New Buy Stock
01:00pm, Monday, 17'th Mar 2025
Vivani Medical (VANI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (NASDAQ: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug impla
Vivani Medical Announces Intent to Spin Off Cortigent Neurostimulation Business
08:30am, Wednesday, 12'th Mar 2025
ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (NASDAQ: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug impla
On Wednesday, Vivani Medical, Inc. VANI said it intends to spin off Cortigent, Inc., a division that develops brain implant devices to help people recover critical body functions, as an independent pu
Vivani reports start of first human trial of GLP-1 implant, says H.C. Wainwright
12:17pm, Friday, 20'th Dec 2024
H.C. Wainwright reiterates a Buy rating and $4 price target on Vivani Medical shares after the company announced that the first-in-human clinical trial of NPM-115, an exenatide implant based on the co
Vivani Medical Announces Initiation of First in Human Clinical Trial with GLP-1 Implant in Obese and Overweight Individuals in Australia
08:30am, Thursday, 19'th Dec 2024
ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), an innovative biopharmaceutical company developing novel, ultra long-acting drug implants, to
Vivani Medical to Present at the Innovation in Obesity Therapeutics Summit West Coast
08:30am, Wednesday, 04'th Dec 2024
ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (NASDAQ: VANI) (the “Company” or “Vivani”), an innovative biopharmaceutical company developing miniaturized, ultra long-acting drug impla
ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), an innovative, biopharmaceutical company developing novel, ultra long-acting drug implants, t
Vivani Medical to Present at the Emerging Growth Conference on September 25, 2024
08:57am, Monday, 23'rd Sep 2024
ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (NASDAQ: VANI) (the “Company” or “Vivani”), an innovative biopharmaceutical company developing miniaturized, ultra long-acting drug impla
Vivani Medical to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
07:10pm, Wednesday, 28'th Aug 2024
ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), an innovative biopharmaceutical company developing miniature, ultra long-acting, subdermal dr
ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), an innovative, biopharmaceutical company developing novel, long-term drug implants, today ann
